FY2025 Consolidated Operating Profit Plunges 53% on One-time Costs
-
Sales: 272,238 million KRW (+1.3% YoY)
-
Operating profit: 4,722 million KRW (-53.0% YoY) due to one-time legal fees and fines
-
Net income: 5,897 million KRW (-38.7% YoY)
-
Total assets: 456,296 million KRW, total liabilities: 217,170 million KRW, total equity: 239,126 million KRW
-
No capital impairment
-
Unaudited; subject to change
KOSPI Filing Information
-
Filing: Change in Sales or Profit Structure of 30% (15% for Large Corporations) or More
-
Company: Ilyang Pharmaceutical (007570)
-
Submission: Ilyang Pharmaceutical Co., Ltd.
-
Receipt: 02-03-2026
-
Under KRX KOSPI Market Division